Taken together, these results illustrate the ability of CD40L to activate the alternative NFκB pathway in MCL cell lines and to substitute the dependency on classical NFκB signaling in REC-1 cells through the activity of alternative NFκB signaling. This evidence concerns the gene CD40LG and mantle cell lymphoma.